You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?

Confirm

Cancel

According to RCTs,

nutritional vitamin D is

ineffective at consistently

reducing PTH and often

delays effective therapy.1,15

 

In contrast, active vitamin D

and active analogues can

reduce PTH, but they:

  • Do not correct 25(OH)D1
  • Increase the risks of hypercalcaemia and hyperphosphataemia1,16–18
/sites/g/files/brlbcj1106/files/2020-03/Background_Bricks_1400-min-min-min.png

LIMITATIONS OF NUTRITIONAL VITAMIN D,
ACTIVE VITAMIN D AND ITS ANALOGUES

/sites/g/files/brlbcj1106/files/2020-06/Effects_on_CKD_2-min.png

25(OH)D: 25-hydroxyvitamin D; CKD–MBD: chronic kidney disease–mineral and bone disorder; FGF-23: fibroblast growth factor-23; PTH: parathyroid hormone; RCT: randomised controlled trial.